Valuation: BeOne Medicines Ltd.

Capitalization 3.37TCr 2.92TCr 2.74TCr 2.48TCr 4.57TCr 2,89000Cr 5.16TCr 32TCr 12TCr 1,32600Cr 13TCr 12TCr 4,87500Cr P/E ratio 2025 *
169x
P/E ratio 2026 * 39.9x
Enterprise value 3.19TCr 2.76TCr 2.6TCr 2.35TCr 4.33TCr 2,73600Cr 4.89TCr 30TCr 12TCr 1,25500Cr 12TCr 12TCr 4,61500Cr EV / Sales 2025 *
6.25x
EV / Sales 2026 * 5.05x
Free-Float
96.17%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.93%
1 week+3.35%
Current month+7.67%
1 month+17.12%
3 months+2.02%
6 months+47.43%
Current year+43.15%
More quotes
1 week 257.41
Extreme 257.41
284.51
1 month 228.92
Extreme 228.925
284.51
Current year 172.67
Extreme 172.67
287.88
1 year 141.31
Extreme 141.31
287.88
3 years 124.46
Extreme 124.46
287.88
5 years 118.18
Extreme 118.18
426.56
10 years 22.51
Extreme 22.51
426.56
More quotes
Manager TitleAgeSince
Chief Executive Officer 56 28/10/2010
President 63 01/04/2018
Director of Finance/CFO 49 22/07/2024
Director TitleAgeSince
Chairman 56 27/01/2016
Director/Board Member 50 01/04/2015
Director/Board Member 51 01/10/2014
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.93%+3.35%+62.64%+93.37% 3.44TCr
-1.24%+5.97%-49.57%-6.86% 5.59TCr
-3.88%-6.41%+33.86%+48.33% 3.55TCr
+0.28%+6.97%+56.66%-28.41% 2.74TCr
-0.23%-1.99%+15.48%-22.94% 2.56TCr
+2.90%+37.99%+58.93%+470.73% 1.88TCr
+0.86%-3.11%+137.78%+1,922.30% 1.47TCr
-5.36%+7.51%+125.72%-61.03% 1.45TCr
-0.44%+2.01%-19.54%-24.81% 1.41TCr
+0.38%-2.97%+92.04%+132.72% 1.13TCr
Average -0.87%+5.67%+51.40%+252.34% 2.52TCr
Weighted average by Cap. -1.13%+5.47%+32.72%+160.60%
See all sector performances

Financials

2025 *2026 *
Net sales 510.17Cr 441.37Cr 415.08Cr 375.72Cr 692.25Cr 44TCr 781.91Cr 4.84TCr 1.89TCr 20TCr 1.91TCr 1.87TCr 74TCr 617.12Cr 533.9Cr 502.09Cr 454.49Cr 837.38Cr 53TCr 945.83Cr 5.85TCr 2.28TCr 24TCr 2.32TCr 2.27TCr 89TCr
Net income 13Cr 11Cr 11Cr 9.6Cr 18Cr 1.12TCr 20Cr 123.65Cr 48Cr 512.84Cr 49Cr 48Cr 1.89TCr 60Cr 52Cr 49Cr 44Cr 82Cr 5.17TCr 92Cr 571.48Cr 222.58Cr 2.37TCr 225.98Cr 221.2Cr 8.71TCr
Net Debt -179.36Cr -155.17Cr -145.93Cr -132.1Cr -243.38Cr -15TCr -274.9Cr -1.7TCr -662.78Cr -7.06TCr -672.9Cr -658.66Cr -26TCr -254.65Cr -220.31Cr -207.18Cr -187.54Cr -345.53Cr -22TCr -390.29Cr -2.42TCr -940.97Cr -10TCr -955.34Cr -935.12Cr -37TCr
More financial data * Estimated data
Logo BeOne Medicines Ltd.
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Employees
11,000
Calendar
More about the company
Date Price Change Volume
16/25/16 264.42 $ -1.93% 3,26,595
13/25/13 269.63 $ -2.50% 3,91,803
12/25/12 276.53 $ +5.38% 7,24,422
11/25/11 262.41 $ -0.38% 2,82,617
10/25/10 263.42 $ -0.14% 4,16,173

Delayed Quote Nasdaq, June 17, 2025 at 01:30 am IST

More quotes
Trading Rating
Investor Rating
ESG MSCI
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
269.63USD
Average target price
331.97USD
Spread / Average Target
+23.12%
Consensus

Quarterly revenue - Rate of surprise